企業プロフィール
Elicio Therapeutics, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ELTX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
3.02 USD (-2.27%)
終値
最終更新: 2026年8月17日
219M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ELTX closed down 2.27% at $3.02. No new same-company headline was identified in the current news window.
企業概要
Lymph-Node-Targeted Immunotherapies
Elicio Therapeutics develops immunotherapies designed to traffic directly to lymph nodes, where immune responses are coordinated. Its amphiphile technology links therapeutic payloads to albumin for delivery into lymphatic tissue.
ELI-002 7P
ELI-002 7P is an off-the-shelf therapeutic cancer vaccine targeting seven common KRAS mutations. It is intended to generate mutation-specific T-cell responses in patients with minimal residual disease after surgery.
Pancreatic Cancer Development
The randomized Phase 2 AMPLIFY-7P study is evaluating ELI-002 7P in patients with resected, KRAS-mutated pancreatic ductal adenocarcinoma, using disease-free survival as its primary endpoint.
今後のカタリスト
- Initiation of a Phase 1 study combining ELI-002 7P with a RAS inhibitor, with or without an anti-PD-1 therapy, in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。